1. Market Research
  2. > Pathology
About 400 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Global Biotechnology, MarketLine

  • $ 350
  • June 2018
  • 34 pages

lymphoma (FL), RA and certain types of ANCA-associated vasculitis, Actemra/ RoActemra, for rheumatoid arthritis, systemic juvenile idiopathic arthritis and polyarticular juvenile idiopathic arthritis, Xolair, for moderate to severe persistent allergic asthma and chronic idiopathic urtic

  • Biotechnology
  • Lymphoma
  • Amgen Inc.
  • Covance Inc.
  • F. Hoffmann-La Roche Ltd.

Aging Populations - Overcoming the challenges of a world with a depleted workforce and elderly populace

  • $ 1495
  • May 2017
  • 38 pages

MARKETLINE THEMATIC REPORT Aging Populations Overcoming the challenges of a world with a depleted workforce and elderly populace Reference Code: ML##-## Publication Date: May 2017 WWW. MARKE TLINE.

  • Pension
  • World
  • Economy

Novo Nordisk A/S - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 169 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas--> Non-Hodgkin' s Lymphoma Pharmaceuticals and Healthcare--> Ther

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Novo Nordisk Group

Biotechnology in Japan

  • $ 350
  • December 2019
  • 49 pages

Alunbrig, a targeted cancer medicine, received accelerated approval from the FDA in April 2017 for the treatment of patients with anaplastic lymphoma kinasepositive (ALKplus) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

  • Biotechnology
  • Lymphoma
  • Pharmaceutical
  • Japan
  • Daiichi Sankyo Company

Kirin Holdings Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 299 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Solid Tumors Address City State Country Website Phone number PARTNER ##: KYOWA HAKKO USA INC ##-##-## Ohtemachi Building, Ohtemachi Chiyoda-ku Tokyo Japan www. kyowahakko-bio. co. jp ## ## ## Kyowa Hakko USA Inc (K

  • Healthcare
  • Lymphoma
  • Neurology
  • Pharmaceutical
  • Therapy

Cleveland BioLabs, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 91 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hema

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Abviva, Inc.

Onxeo SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 80 pages

MARKETLINE FINANCIAL DEALS Vendor, acquirer, target and partner report for Onxeo SA and its subsidiaries.

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Onxeo SA

Mirati Therapeutics Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 68 pages

Specific patient populations include patients with diffuse large Bcell lymphoma (DLBCL) and follicular lymphoma, two tumor types that are classified as non-Hodgkin' s lymphomas (NHL).

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Corporate Finance
  • Mirati Therapeutics, Inc.

Simcere Pharmaceutical Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 106 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas--> Hodgkin' s Lymphoma Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas--> Non-Hodgkin' s Lymphoma Pharmaceuti

  • Healthcare
  • Hospital
  • Lymphoma
  • Pharmaceutical
  • Therapy

Baxter International Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 216 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hema

  • Healthcare
  • Infectious Disease
  • Lymphoma
  • Pharmaceutical
  • Therapy

Neuralstem Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 80 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hema

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Neuralstem, Inc.

Arrowhead Research Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • May 2018
  • 135 pages

lymphoma, and will be preceded by a brief dose finding run-in phase.

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Arrowhead Research Corporation

Catalyst Biosciences Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 74 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hema

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Catalyst Biosciences, Inc.

Merck & Co., Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 505 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hema

  • Healthcare
  • Hospital
  • Lymphoma
  • Pharmaceutical
  • Therapy

Kirin Holdings Company Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • April 2018
  • 178 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Solid Tumors Address City State Country Website Phone number PARTNER ##: KYOWA HAKKO USA INC ##-##-## Ohtemachi Building, Ohtemachi Chiyoda-ku Tokyo Japan www. kyowahakko-bio. co. jp ## ## ## Kyowa Hakko USA Inc (K

  • Healthcare
  • Lymphoma
  • Neurology
  • Pharmaceutical
  • Therapy

Thermo Fisher Scientific Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 82 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hema

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Corporate Finance
  • Thermo Fisher Scientific, Inc.

H. Lundbeck A/S - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 200 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas--> Hodgkin' s Lymphoma Pharmaceuticals and Healthcare--> Therapy

  • Healthcare
  • Lymphoma
  • Neurology
  • Pharmaceutical
  • Therapy

IntelGenx Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 105 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hema

  • Healthcare
  • Hospital
  • Lymphoma
  • Pharmaceutical
  • Therapy

Beckman Coulter, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 138 pages

Flow cytometry is used to analyze cells in blood and other fluids for both research applications and diagnosis of diseases such as leukemia, lymphoma and HIV.

  • Genomics
  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Beckman Coulter, Inc.

Barco N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • May 2018
  • 105 pages

Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hematology--> Lymphomas Pharmaceuticals and Healthcare--> Therapy Area-- > Oncology--> Hema

  • Healthcare
  • Hospital
  • Lymphoma
  • Therapy
  • Barco NV
View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on